Community

Our community narratives are driven by numbers and valuation.

Value any stock for free in seconds

Get alerts and valuation updates

Participate in discussions

Weekly Picks

RenovoRx

Stock_Research_Today

Community Contributor

Revolutionizing Cancer Treatment

A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.

View narrative

US$4.20

75.0% undervalued

371.30%

Revenue growth p.a.

15 days ago

Apple

Investingwilly

Community Contributor

Apple: A Dying Star with an Overpriced Valuation

Intro Apple Inc. (AAPL) has long been one of the most beloved stocks in the market, celebrated for its sleek products and loyal customer base.

View narrative

US$177.34

19.7% overvalued

14.68%

Revenue growth p.a.

Updated

Avino Silver & Gold Mines

Agricola

Community Contributor

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Full disclosure. I am a shareholder at the time of writing this.

View narrative

CA$26.79

87.9% undervalued

78.01%

Revenue growth p.a.

15 days ago

RENK Group

Chris1

Community Contributor

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

In a renewed political landscape where a Trump administration adopts a more interventionist stance toward Ukraine, the United States sharply increases its military aid—providing advanced tank transmissions, power packs, and suspension systems. This pivot alleviates initial concerns among European allies, but it simultaneously reinforces the imperative for Europe to shore up its own defense capabilities.

View narrative

€69.87

24.5% undervalued

15.00%

Revenue growth p.a.

17 days ago

Load previous narratives

Goodfood Market

AnalystConsensusTarget

Consensus Narrative from 1 Analyst

Heat And Eat Launch Will Revitalize Consumer Retail

Key Takeaways Goodfood's new product line and digital enhancements are driving revenue growth and increased customer spending. Strategic acquisitions, ethical certifications, and strong cash management bolster financial stability and brand loyalty.

View narrative

CA$0.25

46.0% undervalued

-9.52%

Revenue growth p.a.

14 days ago

Next Science

AnalystConsensusTarget

Consensus Narrative from 1 Analyst

FDA Engagement And XPERIENCE Will Secure Future Confidence

Key Takeaways Strong growth in key products and a high gross margin suggest potential for future revenue and net margin improvement. Addressing the FDA warning could enhance market confidence and stability, benefiting future earnings and stock valuation.

View narrative

AU$0.27

65.8% undervalued

43.60%

Revenue growth p.a.

14 days ago

Oncopeptides

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

Agreements In Europe And Japan Will Unlock Global Markets

Key Takeaways Strategic agreements in Europe and potential licensing in Japan will unlock major markets, enhancing future earnings and revenue growth. Cost management alongside sales expansion in core European markets aims to achieve cash flow positivity, positively impacting net margins by 2026.

View narrative

SEK 2.50

19.2% undervalued

120.02%

Revenue growth p.a.

14 days ago

GameSquare Holdings

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

Managed Services And Partnerships Will Drive Future Success In 2025

Key Takeaways Divestiture of FaZe Media reduces debt, lowers financial risk, and enhances net margins by focusing on profitable segments. Focus on managed services, SaaS expansion, and strategic partnerships aims to boost revenue, gross margins, and achieve positive cash flow.

View narrative

US$3.33

80.0% undervalued

17.94%

Revenue growth p.a.

14 days ago

Xos

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

Blue Bird And Winnebago Partnerships Will Optimize Operational Efficiency

Key Takeaways Strategic partnerships and expansion in powertrain and utility applications could drive revenue growth and enhance margins. Operational pivots and supplier reshoring could improve working capital and counter tariff impacts, supporting net margin improvement.

View narrative

US$6.33

40.5% undervalued

10.73%

Revenue growth p.a.

14 days ago

Janison Education Group

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

NSW Education Contract And AI Investment Will Improve Efficiency

Key Takeaways Strategic investments in AI technology and executive appointments aim to boost operational efficiency, product innovation, and long-term revenue growth. Expansion in customer pipelines and key contracts provide promising avenues for top-line growth and improved profitability.

View narrative

AU$0.27

47.0% undervalued

3.83%

Revenue growth p.a.

14 days ago

Worksport

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

Launches Of AL4 SOLIS And COR Will Expand Market Footprint

Key Takeaways Shifting focus to higher-margin products and expanding clean energy offerings could significantly enhance profitability and drive robust revenue growth. Expansion into government and fleet sectors, plus new dealer partnerships, aims to boost both consumer and business sales.

View narrative

US$11.00

68.0% undervalued

100.50%

Revenue growth p.a.

14 days ago

Vivos Therapeutics

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

FDA Clearance And Middle East Expansion Will Secure Future Success

Key Takeaways Strategic alliances and clinic acquisitions aim to increase patient conversions, boosting revenue and margins through higher treatment uptake. Successful Middle East expansion and FDA clearance for severe OSA treatment enhance clinical credibility, driving significant international sales and revenue growth.

View narrative

US$5.85

48.0% undervalued

17.50%

Revenue growth p.a.

14 days ago

Curis

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

FDA And EMA Will Accelerate Emavusertib Clinical Trials

Key Takeaways Feedback from regulatory bodies can expedite market entry for emavusertib, potentially accelerating revenue and competitive advantage in the CNS lymphoma space. Financial stability is bolstered by extended cash runway, allowing Curis to sustain operations and invest in R&D for pipeline advancement.

View narrative

US$16.00

87.5% undervalued

33.19%

Revenue growth p.a.

14 days ago

Community

Weekly Picks

Revolutionizing Cancer Treatment

Apple: A Dying Star with an Overpriced Valuation

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

Heat And Eat Launch Will Revitalize Consumer Retail

FDA Engagement And XPERIENCE Will Secure Future Confidence

Agreements In Europe And Japan Will Unlock Global Markets

Managed Services And Partnerships Will Drive Future Success In 2025

Blue Bird And Winnebago Partnerships Will Optimize Operational Efficiency

NSW Education Contract And AI Investment Will Improve Efficiency

Launches Of AL4 SOLIS And COR Will Expand Market Footprint

FDA Clearance And Middle East Expansion Will Secure Future Success

FDA And EMA Will Accelerate Emavusertib Clinical Trials

Value any company in seconds

Popular companies

Community

Weekly Picks

Revolutionizing Cancer Treatment

Apple: A Dying Star with an Overpriced Valuation

Avino a case for USD$20 per share within 5 years (assuming $3,500 gold, $100 silver and $4 copper).

Riding the Defense Boom RENK Sees Revenue Climb at 15% CAGR by FY 2029

Community Investing Ideas

Heat And Eat Launch Will Revitalize Consumer Retail

FDA Engagement And XPERIENCE Will Secure Future Confidence

Agreements In Europe And Japan Will Unlock Global Markets

Managed Services And Partnerships Will Drive Future Success In 2025

Blue Bird And Winnebago Partnerships Will Optimize Operational Efficiency

NSW Education Contract And AI Investment Will Improve Efficiency

Launches Of AL4 SOLIS And COR Will Expand Market Footprint

FDA Clearance And Middle East Expansion Will Secure Future Success

FDA And EMA Will Accelerate Emavusertib Clinical Trials

Value any company in seconds

Popular companies